RT @ThePharmaLetter: Phase III updates on long-term performance of Cosentyx at #EULAR2017 https://t.co/RBvwEvENW8 — ThePharmaLetter (@ThePharmaLetter) June 15, 2017
RT @ThePharmaLetter: Phase III updates on long-term performance of Cosentyx at #EULAR2017 https://t.co/RBvwEvENW8